EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ovid Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-17.81 Mil. Ovid Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Ovid Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ovid Therapeutics EBITDA Margin % Related Terms
Ovid Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OVID vs ARTV, CCCC, RZLT: EBITDA Margin % Comparison
For the Biotechnology subindustry, Ovid Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics (OVID) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #708 out of 941 companies in the Biotechnology industry, placing it in the top 75.2%.
Is Ovid Therapeutics' EBITDA Margin % too high?
Ovid Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Ovid Therapeutics ranks #708 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' EBITDA Margin % compare to ARTV and CCCC?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #708 out of 941 companies for EBITDA Margin %. This places Ovid Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.46, compared to a current price of $2.69 — trading 68.2% below its estimated fair value. The current EBITDA Margin % is 0.00%. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued.
The current stock price of $2.69 is trading 68.2% below its estimated GF Value™ of $8.46.
GuruFocus considers Ovid Therapeutics to be Possible Value Trap.
Key valuation signals for OVID:
EBITDA Margin %: 0.00%
GF Value™: $8.46 vs. price of $2.69 (68.2% below fair value)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score
Get the complete analysis for OVID
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
